Research and Markets: On June 21, 2006, Bayer Completed Its Acquisition of Schering for $21.5 Billion - Industry Snapshot: How Companies Are Using M&As to Strategic Advantage.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c44739) has announced the addition of Industry Snapshot: How Companies Are Using M&As to Strategic Advantage to their offering. Merger and acquisition (M&A) activity in 2005 and the first half of 2006 broke the life science industry's tradition of relying on the pharmaceutical and biotechnology sectors for big deals. During this period, the medical device and diagnostic sectors scored big with a handful of multibillion-dollar deals. In addition, the manufacturers of generic pharmaceuticals experienced a wave of consolidation, as did life science companies in Europe and Japan. Get the Answers You Need to Shape Your Strategy Big pharma companies are increasingly focusing on their core prescription drug prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, businesses and selling off other health care lines. During the period under study, which major pharmaceutical companies were most active in divesting of OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). and other businesses to concentrate on their prescription pharmaceutical business? Until recently, the German pharmaceutical industry largely avoided the consolidation activity that took place throughout the rest of Europe and United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. over the past 20 years. However, on June 21, 2006, Bayer completed its acquisition of Schering for $21.5 billion. What are the reasons behind this changing trend and what do they signify for the future of the German, indeed European, pharmaceutical industry? In January 2006, the largest life sciences merger of the past two years was completed when Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, agreed to pay $27.2 billion for Guidant. Why are investors second-guessing Boston Scientific's acquisition? Thermo Electron's anticipated acquisition of Fisher Scientifi c for $10.6 billion will form the largest single-source supplier of diagnostic equipment and services worldwide and is expected to precipitate further consolidation among other major players in the diagnostic market. How will this merger benefi t both companies? Scope * The top deals: Boston Scientifi c's acquisition of Guidant and Bayer's acquisition of Schering. * Deals by industry segment: big pharma, big biotech, generics makers, and diagnostics. * Deals by geography: M&A activity in Europe and Japan. * Other deal types: technology acquisitions, acquisitions of business units/divisions, product/patent/royalty buyouts, and facility/capacity buyouts. Content Outline: Executive Summary Strategic Considerations Stakeholder Implications Introduction Sizable Deals/Bidding Wars Bayer Acquires Schering Boston Scientific Acquires Guidant Deals by Industry Segment Big Pharma Diagnostics Siemens Inverness Medical Innovations Thermo Electron Thermo Electron Corporation (TMO (NYSE)) (incorporated 1956) is a major provider of analytical instruments and services for a variety of domains. Thermo has revenues of over $2 billion, and employs 11,000 people in 30 countries. Generics Big Biotech Deals by Geography European M&A Activity of Note AstraZeneca Novartis Other European Activities Japanese M&A Activity of Note Other Deal Types Technology Acquisitions of Note Monoclonal Antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). Glycoengineering Acquisitions of Business Units/Divisions Reckitt Benckiser Reckitt Benckiser plc is one of the world's leading manufacturers of cleaning products and a member of the FTSE 100 Index of the largest companies traded on the London Stock Exchange. It is headquartered in the town of Slough just to the west of Greater London. Altana Pharma Product/Patent/Royalty Buyouts Bayer Medtronic Facility/Capacity Acquisitions Novartis Genentech Outlook Big Pharma Diagnostics Big Biotech Europe Japan Tables Figures Companies Mentioned: * Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. * Abgenix * Acon Laboratories * Actavis * Alliance Boots Alliance Boots Limited is a British based pharmaceuticals company, operating as a high street retailer, pharmacist and pharmaceuticals wholesaler. Alliance Boots is the dominant pharmacy chain in Britain with a 17% market share[1]. * Altana Pharma * Amgen * Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 * AstraZeneca * Barr Pharmaceuticals Barr Pharmaceuticals, Inc., (NYSE: [http://www.nyse.com/about/listed/lcddata.html?ticker=BRL BRL]) is global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and * Bayer * Bayer-Schering * Pharmaceuticals * Bayer Diagnostics * Bayer HealthCare * Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec * Bone Care International * Boots Healthcare * International * Boston Scientifi c * Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were * Cambridge Antibody * Technology * Chiron * Daiichi Pharmaceutical * Dainippon Pharmaceutical * Dainippon Sumitomo * Pharmaceutical * Diagnostic Products * Corporation * Eon Labs * Fisher Scientifi c * Fujisawa Pharmaceutical * Genentech * Genzyme * GlaxoSmithKline * GlycArt Biotechnology * GlycoFi * Guidant * Hexal * ID Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. * Inverness Medical * Innovations * Ischemia Technologies * Ivax * Johnson & Johnson * Karlin Technology * KuDos Pharmaceuticals * Medtronic * Merck & Co. * Merck KGaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. * NeuTec Pharma * Novartis * Nycomed * Pfi zer * PharmaDerm * Pliva * Procter & Gamble * Ranbaxy Laboratories * Reckitt Benckiser * Roche * Sankyo * Sanofi -Aventis * Schering * Siemens * Sumitomo Pharmaceutical * Syrrx * Takeda Pharmaceutical * Teva Pharmaceutical * Thermo Electron * Vicuron Pharmaceuticals * Watson Pharmaceuticals * Wyeth * Yamanouchi * Pharmaceutical For more information visit http://www.researchandmarkets.com/reports/c44739 Source: Decision Resources |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion